Management of Anticoagulation after Renal Biopsy
Introduction to Anticoagulation Management
- The American Society of Nephrology recommends that warfarin and antiplatelet agents can be reiniciated after a renal biopsy, with warfarin typically restarted the day after the biopsy and antiplatelet agents restarted 48-72 hours after the biopsy 1
Anticoagulation Therapy
- Warfarin can be reiniciated the day after a renal biopsy, according to the American College of Cardiology 1
- Antiplatelet agents can be reiniciated 48-72 hours after a renal biopsy, as suggested by the American Heart Association 1
- The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) recommends stopping heparin before renal biopsy to minimize the risk of bleeding complications 2
- Unfractionated heparin (UFH) should be stopped before the procedure due to its short half-life, while low molecular weight heparin (LMWH) should be stopped at least 24 hours before the procedure 2
- Warfarin should be stopped 5 days before the procedure to minimize the risk of bleeding complications 2, 1
Risk Factors for Bleeding
- Several factors increase the risk of bleeding after renal biopsy, including anticoagulant use (heparin, warfarin, DOACs), antiplatelet agents (aspirin, P2Y12 inhibitors), renal dysfunction (especially with GFR <30 ml/min), hypertension (uncontrolled blood pressure on day of procedure), and coagulation abnormalities (thrombocytopenia, prolonged PT/INR) 2
Bridging Therapy
- For patients at high risk of thromboembolism (mechanical heart valves, recent thrombosis), bridging therapy with UFH may be necessary when LMWH or warfarin is stopped 3, 4
- The timing of UFH bridging should be stopped 4-6 hours before the procedure, and monitoring of aPTT is recommended before proceeding with biopsy 3, 4